Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges

被引:30
|
作者
Kett, Lauren R. [1 ,3 ]
Dauer, William T. [1 ,2 ]
机构
[1] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Med Scientist Training Program, Ann Arbor, MI USA
关键词
Parkinson's disease; Atp13a2; Kufor-Rakeb syndrome; endolysosomal system; REPEAT KINASE 2; SYNUCLEIN GENE DUPLICATION; CHAPERONE-MEDIATED AUTOPHAGY; ALPHA-SYNUCLEIN; CATHEPSIN-D; LYSOSOMAL DYSFUNCTION; RETROMER COMPLEX; MOUSE MODEL; CELL-DEATH; DEGRADATION;
D O I
10.1002/mds.26797
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Increasingly, genetic, cell biological, and in vivo work emphasizes the role of the endolysosomal system dysfunction in Parkinson's disease pathogenesis. Yet many questions remain about the mechanisms by which primary endolysosomal dysfunction causes PD as well as how the endolysosomal system interacts with -synuclein-mediated neurotoxicity. We recently described a new mouse model of parkinsonism in which loss of the endolysosomal protein Atp13a2 causes behavioral, neuropathological, and biochemical changes similar to those present in human subjects with ATP13A2 mutations. In this Scientific Perspectives, we revisit the evidence implicating the endolysosomal system in PD, current hypotheses of disease pathogenesis, and how recent studies refine these hypotheses and raise new questions for future research. (c) 2016 International Parkinson and Movement Disorder Society.
引用
收藏
页码:1433 / 1443
页数:11
相关论文
共 50 条
  • [41] Design creativity research: recent developments and future challenges
    Goldschmidt, Gabriela
    INTERNATIONAL JOURNAL OF DESIGN CREATIVITY AND INNOVATION, 2019, 7 (04) : 194 - 195
  • [42] Recent Developments and Future Challenges of Differential Phase Shifters
    Zheng, Shaoyong
    2020 IEEE ASIA-PACIFIC MICROWAVE CONFERENCE (APMC), 2020, : 377 - 379
  • [43] Gene therapy for Parkinson's disease: Recent achievements and remaining challenges
    Castro, MG
    David, A
    Hurtado-Lorenzo, A
    Suwelack, D
    Millan, E
    Verakis, T
    Xiong, WD
    Yuan, XP
    Lowenstein, PR
    HISTOLOGY AND HISTOPATHOLOGY, 2001, 16 (04) : 1225 - 1238
  • [44] Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients
    Osborn, Teresia M.
    Hallett, Penelope J.
    Schumacher, James M.
    Isacson, Ole
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2020, 14
  • [45] Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease
    Ye Zhao
    Nicolas Dzamko
    Drugs, 2019, 79 : 1037 - 1051
  • [46] Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa
    Smith, Yoland
    Wichmann, Thomas
    Factor, Stewart A.
    DeLong, Mahlon R.
    NEUROPSYCHOPHARMACOLOGY, 2012, 37 (01) : 213 - 246
  • [47] Targeting LRRK2 in Parkinson's disease: an update on recent developments
    Chan, Sharon L.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (06) : 601 - 610
  • [48] Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa
    Yoland Smith
    Thomas Wichmann
    Stewart A Factor
    Mahlon R DeLong
    Neuropsychopharmacology, 2012, 37 : 213 - 246
  • [49] Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease
    Zhao, Ye
    Dzamko, Nicolas
    DRUGS, 2019, 79 (10) : 1037 - 1051
  • [50] The role of the endolysosomal pathway in a-synuclein pathogenesis in Parkinson's disease
    Smith, Jessica K.
    Mellick, George D.
    Sykes, Alex M.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2023, 16